LONDON – Pharming Group NV has seized on Valeant Pharmaceuticals Inc.'s need to "stabilize" its organization and streamline the portfolio, taking back all U.S. rights to Ruconest (recombinant human C1 esterase inhibitor) in the treatment of acute hereditary angioedema (HAE).